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Abstract
Hepatitis diseases are remaining in the list of significant threats to human 
health. Human hepatitis viruses are basically classified into six major hepatotropic 
pathogens—hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus 
(HCV), hepatitis D virus (HDV), hepatitis E virus (HEV), and hepatitis G virus 
(HGV). Among these different forms of hepatotropic viruses, HAV as the leading 
cause of acute viral hepatitis is characterized as a kind of tiny ribonucleic acid virus 
that is linked to atopic disease. As we know, animal models have been instrumental 
in promoting understanding of complex host-virus interactions and boosting 
the advancement of immune therapies. So far, animal models such as nonhuman 
primates (NHPs) have enabled scientists to mimic and study the pathogenicities and 
host immune responses for hepatitis A infection. With the exception of chimpan-
zees and marmosets, animals like mice, pigs, guinea pigs, and tree shrews can also 
be selected as alternative animal models infected with HAV under laboratory condi-
tions. In order to gain a better insight into hepatitis A pathogenesis and relevant 
contents, this chapter is mainly focused on the research progress in animal models 
of hepatitis A, and discusses the merits and demerits of these alternative models.
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1. Introduction
Various forms of viral hepatitis represent a world health concern and challenge, 
generating a considerable socio-economic burden. Of these, hepatitis A as a type of 
food-borne hepatitis is mainly endemic in developing regions with the condition of 
inadequate sanitation and hygiene, such as in parts of Africa, Asia, Eastern Europe, 
South America, and Middle East [1, 2]. With the improvement of public health, 
the incidence of HAV infections in China have been gradually reduced (published 
data from 1990 to 2017) [3]. Up to now, 1.5 million cases of hepatitis A virus (HAV) 
infections are reported worldwide [2], which indicated that hepatitis A remains a 
primary problem in hygiene and public health. Hepatitis A has a very similar clini-
cal symptom compared to hepatitis E. Except for the severer pathological injuries 
of hepatitis E than that of hepatitis A, both of two are self-limiting diseases, do not 
lead to liver cirrhosis and liver cancer, and transmit via orofecal route and person-
to-person contact [4]. Consequently, HAV-contaminated water, vegetables, fruits, 
blood products, and other foodstuffs, especially undercooked shellfish including 
clams, oysters, and mussels (Figure 1) [5, 6], are the major pathways of infections 
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with hepatitis A [7, 8]. Under certain circumstances, intravenous drug users with 
the collective use of syringes are at risk categories for HAV infections [9], and also 
there exist vertical transmissions of HAV from mother to child but occur very rarely 
(Figure 1) [10]. HAV as the main pathogen causing acute viral hepatitis is classi-
fied as a sole member of the genus Hepatovirus of the family Picornaviridae, which 
includes many medical and veterinary pathogens in 1991 [11–13]. HAV is a single 
linear positive-stranded RNA virus whose genomic full length is approximately 
7500 nucleotides, which contain 5′-noncoding region (UTR), protein coding 
region, and 3′-noncoding region (UTR) (Figure 2) [13]. Researchers have found 
that HAV present in the form of naked, nonenveloped virions in feces aids to the 
viral transmissions through the environment. However, when HAV emerges in 
the blood of infected persons, the virion isolates itself from neutralizing antibod-
ies by the way of producing quasi-envelope in host-derived membranes [14]. 
Epidemiological data showed that the most susceptible populations of HAV are the 
children in early childhood [2], and the disease prevalence exceeds 90% before the 
age of 10 [15], albeit most of infected youngers are usually mild or asymptomatic 
[16]. Hence, accelerating the immunological research and viral vaccine develop-
ment can improve human immunity and reduce the spread of HAV. World Health 
Organization (WHO) recommends that vaccination combating HAV be integrated 
into the national immunization schedule for children aged ≥1 year on the consid-
eration of many factors including cost-effectiveness [17]. What is noteworthiness 
is that, the illness infected with HAV in those people who are older than 60 will be 
very severe [18]. Moreover, HAV superinfections in chronic liver disease (CLD) 
Figure 1. 
Diagram showing the possible transmission routes of HAV.
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sufferers (e.g., hepatitis B or C) are usually associated with raising morbidity and 
mortality [19, 20]. To date, animal model is one of the promising tools in the investi-
gation of human HAV infections. Studies on HAV immunopathological mechanism 
and host immune response mainly used nonhuman primates such as chimpanzees 
and marmosets as animal models. Due to the lack of other alternative animal models 
that support HAV infections, the study of the HAV biology and further develop-
ment of therapies for hepatitis A have been hampered. Here in this chapter, the 
biological features of HAV will be discussed, the animal models of hepatitis A and 
their characteristics will be sketched, and the merits and demerits for these models 
will be analyzed as well.
2. Basic biological features of HAV and beyond
As early as 5000 years ago, hepatitis A-like illnesses were documented in ancient 
China. In Europe, similar disease known as “benign epidemic jaundice” was also 
described during the Hippocratic era [21]. As time goes by, in 1947, McCallum et al. 
termed infectious hepatitis as hepatitis A [22]. In the first half of 1967, Krugman 
et al. found the distinctive features between infectious hepatitis (hepatitis A) 
and serum hepatitis (hepatitis B) in clinical, epidemiological, and immunological 
aspects [23]. By 1973, Feinslone et al. firstly detected hepatitis A in feces of patients 
using the technology of immune electron microscopy (IEM) [24]. Morphologically 
and structurally, the purified HAV virion, having an outer diameter of 27–80 nm, 
is an icosahedral nucleocapsid protein granular which contains one linear positive-
stranded ribonucleic acid (RNA) genome [25]. The genome encodes a single large 
polyprotein of 2227 amino acids [26], which is matured and folded to produce 10 
biologically active viral proteins, including four structural proteins that construct 
the capsid (VP4 (~2.5 kDa), VP2 (24–30 kDa), VP3 (21–28 kDa), and VP1pX) and 
6 nonstructural proteins that are indispensable for replication of the RNA genome 
(2B, 2C, 3A, 3B [VPg], 3Cpro [a cysteine protease], and 3Dpol) (RNA-dependent 
Figure 2. 
The genome structure, protein structure components and overall structure of HAV. Refer to [28, 35, 36].
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RNA polymerase) (Figure 2) [27]. By using standard serological technique and 
molecular identification methods, HAV is identified to belong to merely one single 
serotype, and is divided into seven distinct genotypes of which three genotypes 
(I, II, and VII) that circulate in humans, one genotype (III) isolated from either 
humans or owl monkeys, and other three genotypes (V–VII) exist in nonhuman 
primates [28–30]. Genotypes I, II, and III are sub-classified into subtypes A and 
B (Genotypes IA, IB, IIA, IIB, IIIA, and IIIB) [31]. Molecular epidemiology has 
further revealed that HAV sub-genotype IA is responsible for the most circulations 
among human population [32]. For sub-genotype IB HAV strains, several reports 
have declared that they were associated with food such as frozen strawberries in 
Australia and several countries of Europe [33, 34]. Recent studies of X-ray analysis 
have uncovered that HAV possesses a primitive capsid architecture related to that of 
picorna-like viruses infecting insects, which imply a correlation of primeval evolu-
tion as well as a novel cellular entrance mechanism for viruses [35]. The structure 
information (especially the 3D microstructural study) of viral protein is now a 
robust tool for dissecting their biological functions. In 2018, Stuart et al. reviewed 
updated studies on the structural features of outer protein shell of HAV and 
proposed the future researching scopes including relevant structural elucidations 
of the enveloped particles, as well as the capture of intermediates in the state of 
assembly, attachment, and/or uncoating [36]. In terms of receptor binding mecha-
nism, Wang et al. pointed out that using a receptor mimic mechanism for neutral-
ization of infectivity may hold promise for the therapeutic intervention of hepatitis 
A [37]. With regard to the origin of human HAV, phylogenetic analyses show that, 
in the remote past, these ancient viruses have emerged in different host species, and 
ancestral state reconstructions indicate HAV is likely to have originated in rodents 
[38]. What’s more, investigations should be fundamentally focused on therapeutic 
interventions and new creations of HAV vaccines as a result of hepatitis A vaccine 
is one of the most effective strategy for the treatment of hepatitis A [39]. To date, 
four inactivated monovalent HAV vaccines from different manufactures (Havrix®, 
Epaxal®, Avaxim®, and Vaqta®) have been commercially available to the global 
markets [40]. Other hepatitis A vaccines such as a Chinese live attenuated vaccine 
(H2 strain, Zhejiang Academy of Medical Sciences, Hangzhou, PR China) and a 
Vietnam one are just self-sufficient in domestic production [41]. HAV infections are 
still an important cause of morbidity and mortality in developed countries such as 
the United States [42], let alone other nations with poor sanitation. Therefore, the 
work of scientific research for hepatitis A vaccine is still certainly on the way.
3. Applications of animal models
According to literatures, HAV strains of wild type are quite difficult in propa-
gating in vitro. When culturing in cell-conditioned medium, they show low 
growth rate characteristically, as well as have no apparent cytopathic effects [43]. 
Additionally, HAV has its own special life history: it primarily replicates in the 
hepatic tissue, is excreted in biliary system to reach the intestinal contents [44], 
and is mostly shed in the feces and soil [45], where the viruses may persist for 
an extended period of time [46, 47]. Consequently, it is significantly important 
for researchers to find the proper infected models that aim at the investigation of 
HAV. As Hirai-Yuki and his co-authors have ever pointed out that, it is essential to 
develop improved animal models for the deeper investigations of the molecular and 
cellular mechanisms associated virus-hepatocyte interactions within the distinctive 
environment of liver tissue of hosts [48]. Here are the examples of disease models 
for HAV infections showed in Table 1.
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3.1 NHPs
Broadly speaking, NHPs resemble humans in anatomy, physiology, and pathol-
ogy over any other animals, which make them to be considered as the principal 
models for diseases including HAV infections. Human HAV has successfully 
infected various species of NHPs, such as chimpanzees (Pan troglodytes) [49], 
common marmosets (Callithrix jacchus) [50, 51], Squirrel Monkeys (Saimiri 
sciureus) [52], New World owl monkeys (Platyrrhines) [53], African green mon-
keys (Cercopithecus aethiops) [54], owl monkey (Aotus trivirgatus) [55], brown 
macaques (Macaca arctoides) [56], stump-tailed monkey (Macaca speciosa) [57] 
and tamarins, etc. (Table 1), but the host range of this virus is still narrow [58], 
mainly limited to relatively few species. The most common animal models used 
in laboratories for interrogating HAV infection are mainly marmosets and chim-
panzees, which are of scarce resources (Chimpanzees are so expensive that they 
are not widely available for research use) in most countries. In addition, experi-
mental data indicated that more than 90% of wild chimpanzees carried anti-HAV 
antibodies [59], which made them less suitable for investigating HAV-infectious 
diseases, but chimpanzees reared in captivity are more susceptible to infect hepati-
tis A. Moreover, it is very difficult for laboratory technicians to feed and operate 
experimentally on these two animals in many situations. And quite importantly, 
ethical concerns have advocated the decreasing use of chimpanzees for invasive 
experiments of research [60].
Take chimpanzees for example, they are the candidate experimental subjects 
that are most closely related to humans genetically, and most probably to be simu-
lative and predictive of human outcomes when used as disease models. In 1962, 
Deinhardt et al. launched the initial attemption experiment that used chimpanzees 
to be infected with HAV through inoculating viral materials (serum or feces), but 
Authors/year Animal models Comments Refs
Dienstag 
et al/1975
Chimpanzees Provided evidence for the susceptibility of 
chimpanzees to HAV
[49]
Amado 
et al/2010
Cynomolgus 
monkeys
Cynomolgus monkey was confirmed as a suitable 
model to study HAV infection
[67]
LeDuc 
et al/1983
New World owl 
monkeys
Confirmed the susceptibility of New World owl 
monkey to HAV
[53]
Song et al/2016 Pigs First experimental evidence to demonstrate human 
HAV strains can infect pigs
[76]
Hirai-Yuki 
et al/2016
Mice Provided a new paradigm for viral pathogenesis in 
the liver
[83]
Hornei 
et al/2001
Guinea pigs Useful for studying some aspects of HAV 
pathogenesis and for testing the safety of vaccines.
[88]
Zhan et al/1981 Tree shrews HAV can replicate in tree shrews and are potential 
for candidate models for HAV infections
[97]
Anthony 
et al/2015
Harbor seals Describe the discovery of an HAV-like virus in seals [98]
Liu et al/2019 Pekin ducks There are differences in the pathogenicity of 
different subtypes of DHAV in ducklings
[100]
Wen et al/2019 Ducks Provided new insights into the genetics and 
pathogenesis of DHAV-3
[101]
Table 1. 
Examples of disease models for HAV infections.
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the gained results could not provide conclusive evidences for the transmission of 
infective hepatitis from humans to chimpanzees [61]. Intriguingly, in 1963, Hillis 
presented biochemical and histologic evidences that promisingly proved chim-
panzees as useful as experimental hosts for human hepatitis viruses [62, 63]. In 
the mid-1970s, results of most of numerous publishment, which attempt to spread 
hepatitis A to chimpanzees yielded negative or equivocal results [64]. By 1984, 
Tsiquaye et al. carried out a study on acute hepatitis A infection occurred in hepa-
titis B chimpanzee carriers, which showed that superinfection can significantly 
alter the parameters of HBV chronicity in chimpanzees [65]. The authors pointed 
out that further observations were needed to establish the degree of severity of 
concurrent infection of HBV carriers with HAV, since such changes may have 
implications in some countries where the proportion of HBV carriers is high plus 
hepatitis A is highly prevalent [65]. For the purpose to locate where does the HAV 
might duplicate in the body, in 1989, Cohen and his colleagues conducted a study 
of single chimpanzee involvement in experiment, and found a possible oropha-
ryngeal site for viral replication due to the emergence of HAV in saliva and throat 
swabs [66]. Similarly, Amado and co-authors acquired an experimental result that 
salivary gland was an extrahepatic site for early HAV replication in cynomolgus 
monkeys [67]. In the following two decades, the investigators shifted the focus of 
animal models to other NHPs instead of chimpanzees either because of the high 
cost of chimpanzee research or because of the poor contribution of chimpanzee 
experiments for biomedical applications [68]. Until 2011, Lanford et al. utilized 
three chimpanzee models to study the early innate immune responses to HAV 
infections. They found that HAV has a better property of keeping itself latent 
compared to HCV during early stage of acute resolving infection, and HAV 
infections represent a distinctly different paradigm in the course of intrahepatic 
interactions of virus-host [69].
The chimpanzees have been demonstrated to be an invaluable model tools for 
the investigation on HBV-induced disease pathogenesis and the discovery of novel 
prophylactic drugs and anti-viral therapies [70]. Optimistically, with the advance-
ment of biotechnology, utilizing chimpanzee and other NHPs as disease models 
for HAV infection will surely play significant roles in HAV-associated studies in 
the future.
3.2 Pigs
Compared with NHPs, pigs have several advantages such as easy breeding and 
rearing, convenient handling and fewer ethical concerns, which make them be widely 
used in biomedical research [71]. Under natural conditions, it had been reported that 
HAV infections are being restricted to humans and nonhuman primates [72], and the 
appropriate models used for HAV infection have been restricted to nonhuman pri-
mates [73]. Due to several limitations of such animal models, other surrogate models 
need to be developed for further study. According to literatures, the immune system 
in pigs shares many similarities with humans for over 80% of analytical parameters, 
which made swine as a more suitable and common animal model for humans [74, 75]. 
Moreover, pigs have been used preclinically as disease models for preclinical studies 
usually. Until 2016, Song et al. firstly found the experiment evidence to prove human 
HAV strains can also infect swine [76], which took the first step to approach swine 
models for HAV infections. In this experiment, Song and colleagues observed that 
HAV can survive and replicate in pigs, which have replaced NHPs. However, there 
were no significant changes in the clinical manifestations and serum markers for 
pigs infected with HAV. Finally, they further suggested that pigs might be a suitable 
animal model for future studies related to HAV pathogenesis [76].
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3.3 Chimeric mice/gene knock-out mice
Over the last two decades, mouse models have been successfully used in tack-
ling various biological questions associated with intrahepatic immune response 
mechanisms for disease pathogenesis and clearing of HBV [77]. And also, 
such types of models can be applied to study the adaptive immune response to 
hepacivirus infection and will play roles in vaccine development. However, HAV 
is not capable to replicate in mice due to incompatibilities in the interaction of 
the virus and the innate immune system of mice. Therefore, scientists tackle this 
difficulty by utilizing chimeric mice, which facilitated the successful replication 
of HAV in the body through bypassing the cytosolic pattern recognition recep-
tor, MAVS [78].
Generally speaking, certain cellular receptors are the key molecules that medi-
ate viruses of entry into special kinds of cells in the body. Human membrane 
protein TIM-1 (T cell immunoglobulin and mucin domain protein-1) is a type of 
phosphatidylserine receptor that was firstly described as HAVCR1 [79], which 
helps cellular entry and infection with innumerable conventional enveloped viruses 
that bind phosphatidylserine on their surface [80]. And specially, TIM-3 receptor 
facilitates HAV for its entrance into target cells in humans [81]. However, recent 
research showed that TIM-1 is not an essential hepatovirus factor although its 
PtdSer-binding activity may contribute to the spread of quasi-enveloped virus and 
liver damage in mice [82]. For most of mouse models, wild-type mice are naturally 
resistant to HAV infection [83], and murine cell lines still exist defects in viral 
entry processes functionally [84]. For these reasons, multiple approaches have been 
developed by investigators to generate “humanize” mice at a genetic level to aid 
them susceptible to infection with HAV.
Previously, Yang et al. reported that, by using cell culture method, HAV ablates 
type 1 IFN responses thereby disrupting activation of IRF3 through the MDA5 path-
way [85]. In 2013, Pang used HAV to infect SCID-beige/Alb-uPA mice with chimeric 
human/mouse livers for the purpose to test the susceptibility of mice to HAV. The 
result shows that these chimeric mice are permissive to HAV infection and represent 
valuable small animal models for future studies [86]. In 2016, Hirai-Yuki et al. 
applied the murine models with genetic defects in the induction of type I interferon 
(IFN) responses for HAV infection to reveal a previously undefined link between 
innate immune responses to virus infection and acute liver injury, which furnishes a 
novel paradigm for viral etiopathogenesis in the liver [83]. In 2018, a research team 
of Hirai-Yuki wrote a review of the study on “Murine models of hepatitis A virus 
infection” in which they provided an extensive and in-depth perspective into the 
development and application of mice models for HAV [48]. Additionally, in this 
chapter, it emphatically introduced the mechanism of degrading MAVS via viral 
proteases, in which it facilitates long-term survival of virus and spread through 
escaping from IFN-mediated restriction of virus replication and limiting pathogen-
esis and hepatic damage [48].
Till now, mouse models have been applied to support infections with HBV, HCV, 
and even HAV successfully. This probably has to do with building infections in the 
mouse liver, which is a key point in the development of viral hepatitis. Predictably, 
it has a promising future for utilizing mice as effective models for the investigation 
of HAV infection with the technological development of biomedical models.
3.4 Guinea pigs
The guinea pig models are more similar to humans than other small animal 
models in physiology and immunology. Specifically, the guinea pigs have the 
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property of being analogous to humans in reproductive physiology and estrous 
cycle [87], etc. Guinea pigs have been used as an HAV infection model, but their 
use is limited because of the lack of development of anti-HAV antibodies in 
inoculated guinea pigs. In 2001, Hornei et al. conducted a study to determine 
whether HAV is capable to infect guinea pigs and whether they can be valid as 
a disease model for replicating HAV pathogenesis in humans and for the evalu-
ation of vaccines [88]. The authors found that very low levels of HAV were 
detected in the livers of guinea pigs, which inoculated with human HAV [88]. 
Furthermore, they also described that the experimental guinea pigs shared simi-
lar response pattern with a New World nonhuman primate (Callithrix jacchus) 
after being challenged with HAV materials [88, 89]. The method of using guinea 
pigs to establish models for HAV infection is still under controversy. In 2010, 
de Castro Araujo and colleagues designed a research project to respond to the 
question “Whether HAV is capable to infect guinea pigs?”. However, they failed 
to establish a guinea pig as model for HAV [90].
3.5 Tree shrews
Chinese tree shrew (Tupaia belangeri chinensis), mainly distributing in Yunnan 
and Guangxi provinces in China, is a class of small animals having a closer evo-
lutionary relationship with humans compared to rodents [91]. Tree shrews have 
emerged in the vision of scientists for more than 30 years as a result of having many 
valuable features that are suitable in animals utilized as experimental models in 
biomedical studies [92], particularly in the fields of toxicology and virology [93]. To 
date, there are many attempts to employ tree shrews as models for human disorders 
such as hepatitis B [94] and hepatitis C infections [95, 96]. In 1981, Zhan et al. used 
fecal suspension of hepatitis A patients (concentration: 5%) to infect nine tree 
shrews through oral route, and eventually no apparent clinical symptoms of acute 
hepatitis were found. About 7–13 days after the viral infections, seven tree shrews 
were detected HAV that lies in their stools in 12–27 days, which indicated that HAV 
could reproduce in the body of tree shrews. The experimental results indicated that 
HAV can replicate in tree shrews and are potential for candidate models for HAV 
infections [97]. Additionally, they also found disease symptoms including increased 
alanine transaminase (ALT), hepatic hyperemia, hepatic edema, steatosis, and 
hyperplasia of Kupffer cells in the infected tree shrews, which further manifested 
that HAV can propagate in tree shrews [97].
3.6 Other animal models
Early studies suggested that HAV was unable to lead to infections of any com-
mon small laboratory animals successfully except NHPs. However, this “prejudice” 
has already been challenged and overturned by animal model engineering as well 
as by new scientific discoveries. In 2015, several strains of human HAV have been 
found in seals, which may indicate that the first natural nonprimate HAV to be 
discovered, and provide further understanding for the evolutionary history and 
pathogenicity of HAV [98]. Moreover, in recent years, HAV-associated hepato-
viruses have been found in bats, rodents, hedgehogs [38], duck [99–101], and 
woodchucks [102, 103], which suggested that there may be more candidate animals 
potentially used as animal models of HAV. On the contrary, some scholars believed 
that these new viruses are substantially more divergent from each other and from 
human HAV (including simian HAV), which is in accordance with them being 
assigned to several additional species in taxonomy [78].
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4. Ethical aspects
The animal experiments definitely play an important role in the development 
of life sciences and medical sciences. Therefore, ethical analysis concerning animal 
experiments is essential because it cannot completely avoid the use of animals [104] 
in the process of biomedicine and preclinical medicine research. Specially, NHPs 
act as the particularly valuable models for testing interventions against the Ebola 
and Marburg viruses in the field of studying of current infectious diseases, which 
can effectively objectively simulate human diseases via infections in these animals 
[105], and further contribute to the development of new protective and therapeutic 
vaccines. At a certain level, ethical issues become more important than scientific 
interest for this type of animal test [104] because such infections are often lethal 
to the experimental animals, which are commonly viewed as unethical. Similarly, 
experiments with HAV infection also expose animals (mainly NHPs) to injury or 
disease. Consequently, how to balance the contradiction between ethical challenges 
and NHPs infectious experiments becomes a vitally important subject.
5. Future directions
5.1 Animal model methods
Animal model research is entering a new and exciting stage along with the 
technologies of computational information and molecular biochemistry. For 
example, it is now possible for us to employ genome-edited techniques (e.g., ZFNs, 
TALENs, and CRISPR/Cas) to knockout specific genes, to knock in new genes, or 
to introduce specific mutations, and then to produce valuable animal models that 
benefited for our investigations. However, as we know, “no model is perfect, but 
many are useful” [106]. Therefore, establishing susceptible animal models is one 
of the methods in the research fields of HAV. By using appropriate and reliable 
animal models, virologist can perform a series of studies associated with hepatitis A 
including epidemiologic features, viral infectivity, humoral and cellular immunity, 
cytokine responses, virus pathogenesis, as well as the research and development of 
antiviral vaccinations.
5.2 Cell culture methods
For the development of hepatitis A vaccines, it is worth mentioning that a 
highly effective vaccine against HAV was manufactured by classical inactivation 
of the whole virus generated from cell culture [107], which commendably avoids 
the ethical controversy of using NHPs models. Moreover, there is a need to provide 
more support for the studies of long-term protection vaccines against hepatitis A 
infection [108].
Last but not least, it is very likely that a much wider host range of HAV-
associated viruses will be discovered in other mammalian species in the future [38].
6. Conclusion
The Nobel laureate Peter Medawar have ever succinctly concluded that “No virus 
is known to do good” [109]. However, as we all know, “viruses are not omnipo-
tent.” For hepatitis viruses, the narrow hepatic tissue tropism maybe is the cause 
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of constraining the host ranges of hepatitis viruses to relatively few special host 
species. As previously reported, only one serotype of HAV had been found globally 
[110]. However, according to Bosch et al., there exists the possibility of emergence 
of a novel serotype originated from zoonotic reservoirs [18]. In summary, it is 
necessary to further develop candidate animal models for hepatitis A infection 
although HAV is easily capable of adapting growth in the condition of conventional 
mammalian cell cultures [92].
In recent decades, HAV has been ignored by viral research circles to a certain 
extent due to the research spending and interest have shifted to other hepatotropic 
pathogens. Finally, animal model research, as a preclinical study aiming to hepatitis 
A, can offer a scientific platform to accelerate the pace for drugs screening and 
vaccines development.
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Acronyms and abbreviations
ALT alanine transaminase
CLD chronic liver disease
DHAV duck hepatitis A virus
HAV hepatitis A virus
HBV hepatitis B virus
HCV hepatitis C virus
HDV hepatitis D virus
HEV hepatitis E virus
HGV hepatitis G virus
IEM immune electron microscopy
IFN type I interferon
IRES internal ribosomal entry site
NHPs nonhuman primates
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TALENs transcription activator-like effector nucleases
WHO World Health Organization
ZFNs zinc finger nucleases
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